Evaluating Options for Second-Line HR+, HER2- Breast Cancer TreatmentByKatherine Cohen, MSN, FNP-CApril 3rd 2025Katherine Cohen, MSN, FNP-C, provided insights on what to consider when treating patients with HR+, HER2- breast cancer in the second line of treatment.